Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients

Keyphrases

• Transient Receptor Potential Vanilloid 1 (TRPV1) 100%
• Breast Cancer Patients 100%
• Expression Pattern 25%
• Invasive Breast Carcinoma 25%
• Estrogen 16%
• Breast Cancer 16%
• High Dose 8%
• Diagnosis Treatment 8%
• High Survival 8%
• Survival Rate 8%
• Tumor 8%
• Public Health Burden 8%
• Classical Patterns 8%
• Tumor Growth 8%
• Neurogenesis 8%
• Metastatic Breast Cancer 8%
• Result-oriented 8%
• Patient Survival 8%
• Therapeutic Target 8%
• Malignant Progression 8%
• Increased Dose 8%
• Breast Cancer Subtypes 8%
• Polymodal 8%
• Cancer Pain 8%
• Breast Tissue 8%
• MCF-7 Cancer Cell Line 8%
• Breast Cancer Cell Lines 8%
• Log-rank Test 8%
• Neoplastic Cells 8%
• Subcellular Distribution 8%
• Neoplastic Transformation 8%
• New Molecular Marker 8%
• Breast Cancer Tissues 8%
• Malignant Disease 8%
• Cytotoxic Therapy 8%
• St. Gallen 8%
• Primary Breast Cancer 8%
• ER-Golgi 8%
• Neoplastic Tissue 8%
• Breast Tumor 8%
• Malignant Potential 8%
• Pain Progression 8%
• Immunohistochemical Expression 8%
• Invasive Behavior 8%
• Diagnostic Classification 8%

Medicine and Dentistry

• Breast Cancer 100%
• Vanilloid Receptor 1 100%
• Breast Carcinoma 25%
• Neoplasm 16%
• Disease 16%
• Breast Cancer Cell Line 16%
• Malignant Neoplasm 8%
• Tumor Progression 8%
• Public Health 8%
• Biological Marker 8%
• Cancer Tissue 8%
• Cell Line 8%
• Drug Megadose 8%
• Survival Rate 8%
• MCF-7 8%
• Molecular Marker 8%
• Neurogenesis 8%
• Breast Tissue 8%
• Log Rank Test 8%
• Cytotoxic Chemotherapy 8%
• Cancer Pain 8%
• Metastatic Breast Cancer 8%

Biochemistry, Genetics and Molecular Biology

• Transient Receptor Potential Vanilloid 100%
• Cancer Cell 16%
• Genetic Marker 8%
• Nervous System Development 8%
• Tumor Progression 8%
• Subcellular Localization 8%
• Drug Megadose 8%
• Survival Rate 8%